FDA vaccine head will step down in April after string of controversial decisions

A key U.S. Meals and Drug Administration official who oversees vaccines and biotech therapies will step down from the company following a number of decisions that raised issues inside the trade.

Vinay Prasad, director of the Middle for Biologics Analysis and Analysis, will go away the FDA on the finish of April, an company spokesperson confirmed on Friday. It’s his second departure from the place: He briefly left the publish in July following backlash over his regulatory decisions, and returned solely two weeks later in August.

In a publish on X, FDA Commissioner Marty Makary mentioned the FDA will appoint a successor earlier than Prasad returns subsequent month to the College of California San Francisco, the place he taught earlier than taking the FDA place final yr. Makary mentioned Prasad “bought an incredible quantity completed” throughout his tenure on the company.

Prasad’s determination to step down comes after criticism of the FDA mounted inside the biotech and pharmaceutical trade and amongst former well being officers. Up to now yr, the company has denied or discouraged the approval functions of at the very least eight medication, in keeping with RTW Investments, after taking difficulty with knowledge the businesses used to assist their functions. The FDA additionally initially refused to evaluate Moderna’s flu shot earlier than it later reversed course.

All of these firms accused the FDA of reversing earlier steering in regards to the proof they may use to again their functions, sparking criticism inside the trade that an unreliable regulatory course of might stifle growth of medication for hard-to-treat ailments.

A former FDA official who spoke to CNBC on the situation of anonymity to talk freely on the problem referred to as the reversals the worst sort of regulatory uncertainty as a result of firms say they’re being informed one factor after which expertise one other.

In a press release earlier Friday, an FDA spokesperson mentioned there was “no regulatory uncertainty,” including the company “makes decisions based mostly on the proof, however doesn’t make assurances about outcomes.” The spokesperson mentioned the FDA is “conducting rigorous, unbiased evaluations and never rubber-stamping approvals.”

The latest controversy got here after the FDA discouraged UniQure from making use of for expedited approval of its experimental therapy for Huntington’s illness.

The company, which underwent workers cuts and an overhaul beneath Well being and Human Companies Secretary Robert F. Kennedy Jr., has confronted broader backlash for its drug and vaccine approvals course of. Critics have anxious the company might stifle the event of new therapies and threat the protection of sufferers.

The Wall Road Journal earlier reported Prasad’s departure.